TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $5.22 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.